Scribe Therapeutics Inc. Common Stock 주가 전망 및 핵심 분석

📈 비즈니스 요약

Scribe Therapeutics Inc. is a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression. It uses CRISPR-based platforms, such as ELXR, designed for precise, durable epigenetic silencing of genes without changing the underlying DNA sequence; and XE, designed to support specific and efficient gene editing. The company was incorporated in 2017 and is headquartered in Alameda, California.

💡 주요 지표 브리핑 (Programmatic SEO)

• ✓Scribe Therapeutics Inc. Common Stock의 현재가는 21.65원으로 직전 종가(15원) 대비 변동폭을 기록하고 있습니다.
• ✓PER 0.00 수준으로 해당 업종의 객관적인 밸류에이션 지표를 나타내고 있습니다.
• ✓본 페이지는 단순 정보 제공 목적이며, 투자를 권유하거나 특정 종목을 추천하지 않습니다.